Equities
Health CareHealth Care Equipment & Services
  • Price (USD)56.39
  • Today's Change0.12 / 0.21%
  • Shares traded1.10m
  • 1 Year change52.74%
  • Beta0.9500
Data delayed at least 15 minutes, as of Nov 19 2019 21:00 GMT.
More ▼

Profile data is unavailable for this security.

About the company

DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies. The dental industry encompasses the diagnosis, treatment and prevention of disease and ailments of the teeth, gums and supporting bone. Its principal dental product categories are dental consumable products, dental laboratory products, dental specialty products and dental equipment. Additionally, its consumable medical device products are used for urological and surgical applications. These products are produced by the Company in the United States and internationally and are distributed throughout the world under various brand names, including ANKYLOS, AQUASIL ULTRA, ARTICADENT, ATLANTIS, CALIBRA, CAULK, CAVITRON, CELTRA, DELTON, DENTSPLY, DETREY and DYRACT.

  • Revenue in USD (TTM)3.98bn
  • Net income in USD160.70m
  • Incorporated1983
  • Employees16.40k
  • Location
    Dentsply Sirona Inc13320 Ballantyne Corporate PlCHARLOTTE 28277-3607United StatesUSA
  • Phone+1 (717) 845-7511
  • Fax+1 (302) 636-5454
  • Websitehttps://www.dentsplysirona.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Masimo Corporation913.46m191.13m8.03bn1.50k44.217.2537.528.803.393.3716.1920.670.7582.997.89608,972.7015.8623.4218.0629.2466.8466.4020.9224.155.50--0.000.008.619.42-4.1227.2011.75--
ABIOMED, Inc.820.28m220.82m8.04bn1.37k37.198.1333.849.804.794.7917.8021.920.81561.839.74598,310.8021.9621.8624.3024.6482.8383.5726.9225.194.96--0.000.0029.5933.1893.92103.8973.97--
Henry Schein, Inc.10.69bn491.38m10.08bn18.00k21.033.5514.760.94273.273.3171.0419.351.384.567.36594,003.606.387.7811.3513.6029.8427.714.624.590.921516.950.22540.005.946.67-7.533.378.52--
West Pharmaceutical Services Inc.1.79bn227.00m11.03bn7.70k49.487.4234.126.163.013.0523.7920.100.86985.525.79232,701.3010.688.7512.5810.3432.6932.2112.2810.032.3153.000.115922.767.404.65-12.1212.73-7.648.16
Insulet Corporation693.71m16.53m11.28bn1.17k717.8774.89284.1716.260.25420.254210.982.440.64393.208.81593,424.301.53-6.521.70-7.5365.8159.202.38-8.476.211.580.8675--21.5717.94112.41--85.93--
Varian Medical Systems, Inc.3.23bn317.70m11.74bn7.17k37.276.5840.953.643.463.3835.1119.600.87863.753.05--8.668.6915.4415.1842.4942.579.8611.080.9866--0.1859--10.481.12-11.43-4.73----
Hologic, Inc.3.37bn-35.20m12.50bn6.25k--5.5829.213.71-0.1381-0.156512.438.370.48653.905.48---0.50861.92-0.61922.2951.9653.11-1.054.781.264.380.5727--4.645.8892.31--7.21--
DENTSPLY SIRONA Inc3.98bn160.70m12.52bn16.40k78.822.4725.933.150.71390.721517.7122.750.46422.975.68242,524.401.87-4.062.11-4.5252.2854.124.03-8.881.39162.960.2186---0.17786.2033.65--13.147.61
Steris PLC2.90bn335.96m12.66bn12.00k38.043.9222.344.373.933.9333.8838.080.56797.065.77241,507.806.614.447.184.8843.0041.0111.647.731.8611.190.268345.866.1911.3911.7818.6217.0410.16
Cooper Companies Inc2.61bn464.30m15.15bn12.00k32.824.1920.345.809.328.9652.4272.890.42051.806.70217,775.007.476.478.387.2366.2762.3717.7714.570.72946.570.33390.983518.419.79-4.933.661.680.00
Teleflex Incorporated2.56bn441.69m15.96bn15.20k36.735.5924.366.249.399.4354.3861.650.41042.486.63168,159.507.094.877.765.5557.0953.7917.2811.131.445.150.41226.2814.077.62-25.365.364.910.00
Data as of Nov 19 2019. Currency figures normalised to Dentsply Sirona Inc's reporting currency: US Dollar USD

Institutional shareholders

48.32%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 201925.61m11.43%
Generation Investment Management LLPas of 30 Sep 201916.59m7.40%
Artisan Partners LPas of 30 Sep 201911.87m5.30%
BlackRock Fund Advisorsas of 30 Sep 201910.58m4.72%
SSgA Funds Management, Inc.as of 30 Sep 20199.62m4.29%
Veritas Asset Management LLPas of 30 Sep 20199.11m4.06%
Select Equity Group LPas of 30 Sep 20197.44m3.32%
First Eagle Investment Management LLCas of 30 Sep 20196.29m2.80%
Mackenzie Financial Corp.as of 30 Sep 20195.68m2.54%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 20195.52m2.46%
More ▼
Data from 30 Sep 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.